ArticleFrontiers in immunology2025
Integrating bioinformatics to explore HPV-31 and HPV-52 E6/E7 proteins: from structural analysis to antigenic epitope prediction.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cervical cancer is the most common malignant neoplasm of the female reproductive tract. Infection with human papillomavirus (HPV) has been strongly associated with cervical cancer. Previous bioinformatics studies have examined the E6 and E7 proteins of high-risk HPV types; however, subtype-specific analyses for HPV-31 and HPV-52 remain limited. Understanding the structure and properties of the E6 and E7 proteins of HPV-31 and HPV-52 is crucial to elucidating their functions and advancing vaccine development. Methods: A bioinformatics approach was employed to predict the physicochemical properties, hydrophilicity, protein structure, glycosylation sites, phosphorylation sites, terminal positions, signal peptide cleavage sites, transmembrane regions, homology, and dominant epitopes of the E6 and E7 proteins of HPV-31 and HPV-52. Results: For HPV-31 E6, an instability index (II) of 43.93 indicated that the protein is unstable; potential B-cell epitopes were identified at residues 55-61 (RDDTPYG), 112-116 (PEEKQ), and 125-131 (FHNIGGR), while T-cell epitopes were predicted at residues 45-53 (FAFTDLTIV) and 72-80 (KVSEFRWYR). HPV-52 E6 exhibited an instability index (II) of 55.57, with B-cell epitopes at residues 110-119 (LCPEEKERHV) and 129-141 (MGRWTGRCSECWR), and T-cell epitopes at residues 45-53 (FLFTDLRIV) and 82-87 (SLYGKT). HPV-31 E7, with an instability index (II) of 51.05, exhibited B-cell epitopes at residues 8-17 (QDYYLDLQP), 16-20 (QPEAT), 29-41 (PDSSDEEDVIDEP), and 42-48 (AGQAKPDT), and T-cell epitopes at residues 7-15 (TLQDYVLDL) and 82-90 (LLMGSFGIV). HPV-52 E7, with an instability index (II) of 49.15, exhibited B-cell epitopes at residues 11-19 (YILDLQPET), 23-27 (HCYEQ), 29-38 (GDSSDEEDTD), and 36-48 (DTDGVDRPDGQAE), and T-cell epitopes at residues 53-59 (NYYIVTY) and 84-90 (MLLGTLQ). Discussion: In summary, the E6 and E7 proteins of HPV-31 and HPV-52 contain dominant epitopes for both T cells and B cells. These findings delineate subtype-specific immunogenic regions and establish a foundation for experimental validation and vaccine design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.